Avanos (AVNS) Q3 2025: Specialty Nutrition Surges 14.5% as Portfolio Reshaping Accelerates
Avanos delivered a pivotal third quarter, with double-digit specialty nutrition growth and decisive portfolio moves sharpening its strategic focus. The company’s exit from low-return assets and targeted M&A, alongside a $15–20 million cost reset, set a new baseline for profitability. However, persistent tariff headwinds and a supply chain overhaul signal a complex path to sustained margin expansion in 2026.
Summary
- Portfolio Transformation Drives Growth: Divestitures and the Nexus acquisition sharpened segment focus and improved the growth profile.
- Cost Structure Overhaul Underway: Streamlined R&D and management cuts target $15–20 million in annual savings by 2026.
- Tariff Mitigation Remains Critical: Supply chain investments and lobbying efforts are central to margin recovery next year.
Performance Analysis
Avanos’ third quarter results underscore the company’s pivot toward higher-growth, higher-margin segments, with the specialty nutrition systems (S&S) portfolio delivering 14.5% organic growth—well above market averages and now the clear engine of the business. This segment, which includes long-term, short-term, and neonatal enteral feeding, benefited from robust U.S. demand and the successful rollout of the CoreGrip tube retention system, a product designed to reduce complications in tube feeding patients.
The pain management and recovery segment posted 2.4% normalized organic growth, led by double-digit gains in radiofrequency ablation (RFA), a minimally invasive pain therapy. However, surgical pain was flat, and the Game Ready portfolio faced ongoing pressure, prompting a strategic rental business transition to WRS Group. Operating profit margins improved in both key segments, but tariff-related manufacturing costs—estimated at $18 million for the year—continued to weigh on gross margin and required ongoing mitigation efforts.
- Segment Outperformance: S&S now anchors Avanos’ growth, with all subcategories posting double-digit gains and comprising the majority of revenue momentum.
- Portfolio Pruning: The divestiture of the hyaluronic acid (HA) business and plans to exit IV infusion signal a disciplined approach to capital allocation.
- Operating Leverage: Cost discipline and higher volumes drove a 130 basis point margin improvement in S&S and a 200 basis point lift in pain management recovery.
Free cash flow of $7 million for the quarter was impacted by higher capital expenditures tied to supply chain shifts, but the balance sheet remains robust with $70 million in cash and leverage well below one turn, supporting ongoing M&A capacity.
Executive Commentary
"Our strategic imperatives are to accelerate growth in our strategic business segments, manage and mitigate the impact of tariffs, realize more operating efficiencies, improve or divest underperforming assets, and acquire businesses that are synergistic with our specialty nutrition systems and pain management and recovery strategic segments."
David Pacitti, Chief Executive Officer
"Operating profit for our specialty nutrition system segment for the third quarter was 20%, a 130 basis point improvement compared to a year ago, reflecting a higher volume of sales partially offset by unfavorable tariff impacts."
Scott Gallivan, Senior Vice President and Chief Financial Officer
Strategic Positioning
1. Specialty Nutrition as Core Growth Engine
The S&S segment is now Avanos’ primary growth driver, with above-market expansion across long-term, short-term, and neonatal enteral feeding. The successful adoption of innovation like CoreGrip and the expansion into neonatal care via the Nexus Medical acquisition demonstrate a clear focus on high-value, high-barrier markets.
2. Portfolio Rationalization and M&A Discipline
Avanos is actively pruning low-return businesses, as shown by the HA divestiture and plans to exit IV infusion. Simultaneously, bolt-on acquisitions like Nexus Medical are targeted at expanding the company’s footprint in attractive, adjacent markets, with management confirming appetite for further deals, especially in S&S.
3. Cost Structure Reset and R&D Hybridization
The company is executing a $15–20 million cost savings plan, centered on organizational flattening and a hybrid R&D model that leverages both internal teams and external partners. This approach aims to accelerate product launches and improve accountability, while freeing management bandwidth for core initiatives.
4. Tariff Mitigation and Supply Chain Realignment
Tariff exposure remains a material drag, but Avanos is investing in supply chain shifts—specifically, exiting China for neonatal syringe production by mid-2026—and leveraging temporary exemptions and industry lobbying to blunt the impact. These moves entail higher near-term capex but are expected to restore margin resilience by 2026.
5. Focused Capital Deployment and Balance Sheet Strength
With $70 million in cash and low leverage, Avanos maintains the flexibility to pursue strategic M&A while funding operational transformation. The company’s disciplined capital allocation is evident in its willingness to divest, invest, and partner as needed to drive long-term value.
Key Considerations
This quarter marks a turning point in Avanos’ transformation, with decisive actions to reshape the portfolio, realign cost structure, and insulate the business from external shocks. Investors should weigh the sustainability of S&S growth, the pace of cost realization, and the trajectory of tariff mitigation as the company heads into 2026.
Key Considerations:
- Tariff Disruption Remains Material: Ongoing tariff costs require execution of mitigation strategies and supply chain exits to restore margin stability.
- Cost Savings Execution Risk: Realizing the full $15–20 million in targeted savings depends on successful organizational streamlining and R&D hybridization.
- M&A Integration and Pipeline Delivery: Recent and future bolt-ons must deliver on growth and accretion promises, while product development accelerates via the new hybrid model.
- Segment Growth Sustainability: S&S faces normalization in Q4 after distributor order pull-forward and one-time international wins in 2024.
Risks
Tariff headwinds, especially from China and Mexico, continue to pressure gross margins and require effective mitigation and supply chain execution. Portfolio transition risk is present as the company exits legacy businesses and integrates new acquisitions. Execution on cost savings and R&D hybridization will be critical to margin improvement and future competitiveness. The company also faces industry reimbursement changes and regulatory uncertainty, particularly in pain management.
Forward Outlook
For Q4 2025, Avanos guided to:
- Normalized S&S growth moderating after prior distributor order pull-forward
- Continued positive momentum in RFA and pain management, with surgical pain stable
For full-year 2025, management raised and narrowed guidance:
- Revenue of $690 to $700 million
- Adjusted EPS of $0.85 to $0.95
Management emphasized:
- Tariff mitigation and supply chain exit from China as key to 2026 margin recovery
- Continued focus on M&A, especially in S&S, with active deal pipeline
Takeaways
Avanos is executing a clear transformation, with specialty nutrition now the core growth engine and a disciplined approach to portfolio management and cost structure. Sustained improvement depends on successful tariff mitigation and acceleration of new product development.
- Portfolio Focus Drives Growth: S&S outperformance and targeted M&A are reshaping Avanos’ revenue mix and long-term profile.
- Cost and Tariff Actions Are Pivotal: Margin expansion will hinge on cost savings delivery and effective supply chain realignment in 2026.
- Future Watchpoints: Monitor S&S growth durability, cost realization pace, and the impact of further M&A on segment profitability.
Conclusion
Avanos’ Q3 2025 results reflect a company in active transformation, with strong specialty nutrition momentum and decisive portfolio actions setting the stage for improved growth and profitability. The path forward will be defined by execution on cost, supply chain, and product pipeline acceleration as tariff and integration risks persist.
Industry Read-Through
Avanos’ experience highlights the importance of portfolio discipline, targeted M&A, and agile cost management in medtech as reimbursement and tariff volatility persist. Companies with exposure to international supply chains will need to prioritize supply chain resilience and margin protection, while those in specialty segments may see outsized returns from focused innovation and bolt-on acquisitions. Sector peers should note the operational and capital allocation flexibility required to navigate a dynamic regulatory and macro environment.